Additionally, this data shows that the HS-SY-II cell line is highly heterogeneous, and raises the possibility that the tumor cells that contribute to the xenograft growth in vivo may not be representative of the in vitro cell line, potentially explaining the differences in the phenotypic effects of EZH2 inhibition in vitro vs. in vivo. Here, EZH2 is linked to neoplasm.